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Abstract
Most approaches to machine learning from electronic health data can only predict a single end-
point. Here, we present an alternative that uses unsupervised deep learning to simulate detailed
patient trajectories. We use data comprising 18-month trajectories of 44 clinical variables from
1908 patients with Mild Cognitive Impairment or Alzheimer’s Disease to train a model for personal-
ized forecasting of disease progression. We simulate synthetic patient data including the evolution
of each sub-component of cognitive exams, laboratory tests, and their associations with baseline
clinical characteristics, generating both predictions and their confidence intervals. Our unsuper-
vised model predicts changes in total ADAS-Cog scores with the same accuracy as specifically
trained supervised models and identifies sub-components associated with word recall as predictive
of progression. The ability to simultaneously simulate dozens of patient characteristics is a crucial
step towards personalized medicine for Alzheimer’s Disease.
∗ drckf@unlearn.ai; authors listed alphabetically.
† Data used in the preparation of this article were obtained from the Coalition Against Major Diseases
database (CAMD). As such, the investigators within CAMD contributed to the design and implementation
of the CAMD database and/or provided data, but did not participate in the analysis of the data or the
writing of this report.
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I. INTRODUCTION
Two patients with the same disease may present with different symptoms, progress at
different rates, and respond differently to the same therapy. Understanding how to pre-
dict and manage differences between patients is the primary goal of precision medicine [1].
Computational models of disease progression developed using machine learning approaches
provide an attractive tool to combat such patient heterogeneity. One day these compu-
tational models may be used to guide clinical decisions; however, current applications are
limited both by the availability of data and by the ability of algorithms to extract insights
from those data.
Most applications of machine learning to electronic health data have used techniques
from supervised learning to predict specific endpoints [2–7]. An alternative to developing
separate supervised models to predict each characteristic is to build a single model that
simultaneously predicts the evolution of many characteristics. Statistical models based on
artificial neural networks (Deep Learning) provide one avenue for developing tools that can
simulate patient progression in detail [8–10].
Clinical data present a number of challenges that are not easily overcome with current
approaches to deep learning [11]. For example, most clinical datasets contain multiple types
of data (i.e., they are “multimodal”), have a relatively small number of samples, and many
missing observations. Dealing with these issues typically requires extensive preprocessing [3]
or simply discarding variables that are too difficult to model. For example, one recent study
focused on only four variables that were frequently measured across all 200,000 patients in
an electronic health dataset from an intensive care unit [9]. Developing methods that can
overcome these limitations is a key step towards broader applications of machine learning
in precision medicine.
Precision medicine is especially important for complex disorders where patients exhibit
different patterns of disease progression and therapeutic responses. Alzheimer’s Disease
(AD) and Mild Cognitive Impairment (MCI) are complex neurodegenerative diseases with
multiple cognitive and behavioral symptoms [12]. The severity of these symptoms is usually
assessed through exams such as the Alzheimer’s Disease Assessment Scale (ADAS) [13] or
Mini Mental State Exam (MMSE) [14]. The heterogeneity of AD and related dementias
makes these diseases difficult to diagnose, manage, and treat, leading to calls for better
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methods to forecast and monitor disease progression and to improve the design of AD clinical
trials [15].
A variety of disease progression models have been developed for MCI and AD using clinical
data [16–20] or imaging studies [21–29]. Although previous approaches to forecasting disease
progression have proven useful [30, 31], they have focused on predicting a single endpoint,
such as the change in the ADAS Cognitive (ADAS-Cog) score from baseline. Given that AD
is heterogeneous and multifactorial, we set out to model the progression of more than just
the ADAS-Cog score. We accomplished this by simulating the progression of entire patient
profiles, describing the evolution of each sub-component of the ADAS-Cog and MMSE scores,
laboratory tests, and their associations with baseline clinical characteristics.
The manuscript is structured as follows. Section II A describes our data processing steps
and Section II B describes our machine learning model. Section III A assesses the goodness-
of-fit of our machine learning model. Predictions for individual components are discussed in
Section III B. Section III C assesses the accuracy of our approach, which simulates each sub-
component of the cognitive scores, at predicting changes in overall disease activity measured
by the ADAS-Cog exam. Finally, Section IV discusses implications.
II. METHODS
A. Data Processing
Our statistical model was trained and tested on data extracted from the Coalition Against
Major Diseases (CAMD) Online Data Repository for AD (CODR-AD) [32, 33]. The devel-
opment and composition of this database have been previously described in detail [33]. The
CAMD database contains 6500 patients from the placebo arms of 24 clinical trials on MCI
and AD. These trials have varying duration, visit frequency, and inclusion criteria; nearly
all patients have no data beyond approximately 18 months. We chose a 3-month spacing be-
tween time points based on the visit frequency of the bulk of long-lasting patients to ensure
that most patients had no gaps in their data. The falloff in patient data after the 18-month
time point led us to select that as the final time point. Therefore, patient trajectories are
represented by 7 time points (0, 3, 6, 9, 12, 15, and 18 months).
Data in the CAMD database is stored in the CDISC format [34, 35]. The covariates
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used in our statistical model of AD progression originate from tables in the database on
demographics, disposition events, laboratory results, medical histories, questionnaires, sub-
ject characteristics, subject visits, and vital signs. We designated some variables, such as
height, as static. Multiple values for any of the static variables were averaged to produce
a single estimate. Time-dependent variables were bucketed into 90-day windows centered
on each time point. Multiple entries in any window were averaged, or extremal values were
taken as appropriate. Any data with units (such as laboratory tests) were converted to a
common unit for each test for all patients (e.g., g/L for triglycerides). Results for both
the ADAS-Cog and MMSE tests were available for many patients to the level of individual
components. Individual question data were available for some patients, which we aggregated
into component scores. A final processing step converted data into numerical values more
suitable for statistical modeling. Categorical variables were one-hot encoded and positive
continuous variables were log-transformed and standardized. All variables were transformed
back to canonical form before analysis.
Our statistical model can perform imputation of missing data during training. However,
using covariates that are missing in a large fraction of patients would lead to poor perfor-
mance. Therefore, we chose 44 variables that were observed in a reasonably large fraction of
patients. Tables I and II describe each of the variables included in our analysis. Because we
are interested in modeling AD progression, we focused on patients in the CAMD database
with long trajectories. This led us to select the 1908 patients from CAMD that have a valid
ADAS-Cog score (i.e., data is not missing for any of the 11 components) for either of the
15-month or 18-month time points.
To summarize, we extracted 18-month longitudinal trajectories of 1908 patients with
MCI or AD covering 44 variables including the individual components of the ADAS-Cog and
MMSE scores, laboratory tests, and background information. The patients were randomly
divided into a training group of 1335 patients, a validation group of 95 patients, and a testing
group of 478 patients. The training group was only used in learning parameters of the model;
the validation group was only used to monitor metrics during training, and the testing group
was only used to evaluate the performance of our model. Each patient profile consisted of 44
covariates (Tables I and II) that were classified as binary, ordinal, categorical, or continuous.
Patient trajectories described the time evolution of all 44 variables in 3-month intervals.
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Category Name Type Temporal
ADAS Commands Ordinal Yes
ADAS Comprehension Ordinal Yes
ADAS Construction Ordinal Yes
ADAS Delayed Word Recall Ordinal Yes
ADAS Ideational Ordinal Yes
ADAS Instructions Ordinal Yes
ADAS Naming Ordinal Yes
ADAS Orientation Ordinal Yes
ADAS Spoken Language Ordinal Yes
ADAS Word Finding Ordinal Yes
ADAS Word Recall Ordinal Yes
ADAS Word Recognition Ordinal Yes
MMSE Attention and Calculation Ordinal Yes
MMSE Language Ordinal Yes
MMSE Orientation Ordinal Yes
MMSE Recall Ordinal Yes
MMSE Registration Ordinal Yes
TABLE I. Cognitive variables included in the model.
B. Machine Learning
A statistical model is generative if it can be used to draw new samples from an inferred
probability distribution. Generative modeling of clinical data involves two tasks: i) randomly
generating patient profiles with the same statistical properties as real patient profiles and ii)
simulating the evolution of these patient profiles through time. Each of these tasks is com-
plicated by common properties of clinical data, namely that they are typically multimodal
and have many missing observations. Moreover, patient progression is best regarded as a
stochastic process and it is important to capture the inherent randomness of the underlying
processes in order to make accurate forecasts.
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Category Name Type Temporal
Laboratory Alanine aminotransferase Continuous Yes
Laboratory Alkaline phosphatase Continuous Yes
Laboratory Aspartate aminotransferase Continuous Yes
Laboratory Cholesterol Continuous Yes
Laboratory Creatine kinase Continuous Yes
Laboratory Creatinine Continuous Yes
Laboratory Gamma glutamyl transferase Continuous Yes
Laboratory Hematocrit Continuous Yes
Laboratory Hemoglobin Continuous Yes
Laboratory Hemoglobin a1c Continuous Yes
Laboratory Indirect bilirubin Continuous Yes
Laboratory Potassium Continuous Yes
Laboratory Sodium Continuous Yes
Laboratory Triglycerides Continuous Yes
Clinical Blood pressure (diastolic) Continuous Yes
Clinical Blood pressure (systolic) Continuous Yes
Clinical Heart rate Continuous Yes
Clinical Weight Continuous Yes
Clinical Dropout Continuous Yes
Background Age at baseline Continuous No
Background Geographic region Categorical No
Background Initial diagnosis (AD or MCI) Binary No
Background Past cardiovascular event Binary No
Background ApoE 4 allele count Ordinal No
Background Race Categorical No
Background Sex Binary No
Background Height Continuous No
TABLE II. Laboratory, clinical, and background variables included in the model.
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FIG. 1. Overview of the data and model. A) Study data built from the CAMD database
consists of 18-month longitudinal trajectories of 1908 patients with MCI or AD. Our model uses
44 variables, including the individual components of the ADAS-Cog and MMSE scores, laboratory
tests, and background information. B) To capture time dependence, we model the joint distribution
of the data at time t+1 and the data at time t using a Conditional Restricted Boltzmann Machine
(CRBM) with ReLU hidden units. Multimodal observations are modeled with different types of
units in the visible layer and missing observations are automatically imputed.
Let xi(t) be a vector of covariates measured in patient i at time t. Creating a generative
model to solve (i) involves finding a probability distribution P (x) such that we can randomly
draw xi(t = 0) ∼ P (x). Solving problem (ii) involves finding a conditional probability
distribution P (x(t)|x(t − 1)) so that we can iteratively draw xi(t) ∼ P (xi(t)|xi(t − 1)) to
generate a patient trajectory.
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Our statistical model for patient progression is a latent variable model called a Condi-
tional Restricted Boltzmann Machine (CRBM) [36–39]. To construct the model, the covari-
ates were divided into two mutually exclusive subsets: static covariates that were determined
solely from measurements at the beginning of the study xstatici (t = 0), and dynamic covari-
ates that changed during the study xdynamici (t). To train the model, we defined vectors
vi(t) = {xdynamici (t),xdynamici (t− 1),xstatici (t = 0)} by concatenating neighboring time points
with the static covariates. All neighboring time points are combined into a single dataset
used to train a single statistical model that applies to all neighboring time points. Rather
than directly modeling the correlations between these covariates, a CRBM models these
correlations indirectly using a vector of latent variables hµ(t). These latent variables can
be interpreted in much the same way as directions identified through principal components
analysis.
The CRBM is a parametric statistical model where the probability density is defined as
p(v,h) = Z−1 exp
(∑
j
aj(vj) +
∑
µ
bµ(hµ) +
∑
jµ
Wjµ
vj
σ2j
hµ
2µ
)
, (1)
and Z is a normalization constant that ensures the total probability integrates to one. Here,
aj(vj) and and bµ(hµ) are functions that characterize the data types of covariate vj and latent
variable hµ, respectively. The parameters σj and µ set the scales of vj and hµ, respectively.
We used 50 normally distributed latent variables that were lower truncated at zero, which
is known as a rectified linear (ReLU) activation function in the machine learning literature
[40]. To deal with missing data, we divide the visible vector v into mutually exclusive
groups vmissing and vobserved and impute the missing values by drawing from the conditional
distribution p(vmissing |vobserved).
Traditionally, CRBMs are trained to maximize the likelihood of the data under the model
using stochastic maximum likelihood [41]. Recent results have shown that one can improve
on maximum likelihood training of RBMs by adding an additional term to the loss function
that measures how easy it is to distinguish patient profiles generated from the statistical
model from real patient profiles [42]. Therefore, we used a combined maximum likelihood
and adversarial training method to fit the CRBM; more details of the machine learning
methods are described in the Supporting Information. An overview of our statistical model
is depicted in Figure 1.
We generated two types of synthetic patient trajectories with a CRBM: i) synthetic
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trajectories starting from baseline values for real patients, and ii) entirely synthetic patients.
The first type is useful for many tasks in precision medicine and clinical trial simulation,
while the second type has interesting applications for maintaining the privacy of clinical
data [43]. To generate trajectories of type (i), an initial population of patients was selected
and then the model was used to predict their future state. To accomplish this, we started
with baseline data and used the CRBM to iteratively add new time points. To generate
trajectories of type (ii), entirely synthetic patients were generated by first simulating the
baseline data, then iteratively adding new time points so that the patient data was entirely
simulated.
III. RESULTS
A. General model performance
As an initial measure of performance, we assessed the ability of the CRBM to generate
marginal distributions of each variable using entirely synthetic patients. The CRBM gener-
ated time series that accurately captures the marginal distributions of cognitive exam scores,
laboratory tests, and clinical data of real AD patients (Supporting Information). Beyond
marginal distributions, equal-time and lagged autocorrelations are more important factors in
forecasting disease progression, so we assessed the CRBM’s ability to model these data. En-
tirely synthetic patient trajectories have correlations that model the data well (Figure 2A).
The variables can be reasonably grouped into three categories: cognitive scores, laboratory
and clinical tests, and background information. There are strong correlations between vari-
ables belonging to the same category but only weak inter-category correlations (Figure 2A).
Unfortunately, this also implies that neither the laboratory tests nor background variables
are strongly correlated with the primary clinical endpoints captured by cognitive assessments
for AD. Even though the CRBM only incorporates a direct connection between neighboring
time points, this is sufficient to reproduce equal-time and lagged autocorrelations between
variables (Figure 2B-D), even for time lags greater than 3 months. Collectively, these results
suggest the model has excellent generative performance.
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FIG. 2. The model has good generative performance. A) Correlations between variables as
predicted by the model (below the diagonal) and calculated from the data (above the diagonal).
Components of the cognitive scores are strongly correlated with each other, but not with other
clinical data. B) Scatterplot of observed vs predicted correlations for each time point, over all times.
C) Scatterplot of observed vs predicted autocorrelations with time lag of 3 months. D) Scatterplot
of observed vs predicted autocorrelations with time lag of 6 months. The color gradient in B – D
represents the fraction of observations where the variables used to compute the correlation were
present; lighter colors mean more of the data was missing. The R2 values shown are from a least
squares fit weighted by this fraction (of data present when computing the correlations).
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CRBM RF CRBM RF CRBM RF CRBM RF CRBM RF CRBM RF
ADAS Commands
ADAS Comprehension
ADAS Construction
ADAS Delayed Word Recall
ADAS Ideational
ADAS Naming
ADAS Orientation
ADAS Remember Instructions
ADAS Spoken Language
ADAS Word Finding
ADAS Word Recall
ADAS Word Recognition
MMSE Attention Calculation
MMSE Language
MMSE Orientation
MMSE Recall
MMSE Registration
Diastolic Blood Pressure
Systolic Blood Pressure
Heart Rate
Weight
Alanine Aminotransferase
Alkaline Phosphatase
Aspartate Aminotransferase
Cholesterol
Creatine Kinase
Creatinine
Gamma Glutamyl Transferase
Hematocrit
Hemoglobin
Hemoglobin A1C
Indirect Bilirubin
Potassium
Sodium
Triglycerides
0.78 0.81
0.72 0.84
0.72 0.77
0.49 0.50
0.77 0.78
0.59 0.64
0.62 0.64
0.70 0.73
0.66 0.69
0.66 0.63
0.52 0.55
0.68 0.70
0.85 0.84
0.78 0.86
0.65 0.64
0.84 0.82
0.92 0.99
0.80 0.79
0.79 0.78
0.79 0.78
0.19 0.16
0.72 0.75
0.45 0.49
0.76 0.78
0.56 0.59
0.71 0.76
0.47 0.51
0.54 0.63
0.59 0.54
0.56 0.49
0.35 0.51
0.62 0.60
0.84 0.82
0.81 0.81
0.67 0.68
0.85 0.82
0.75 0.81
0.71 0.75
0.49 0.52
0.73 0.75
0.67 0.66
0.61 0.62
0.75 0.75
0.70 0.79
0.69 0.67
0.53 0.55
0.74 0.74
0.75 0.67
0.78 0.75
0.71 0.69
0.87 0.84
0.97 0.88
0.87 0.85
0.85 0.84
0.87 0.84
0.27 0.17
0.85 0.85
0.48 0.89
0.87 0.84
0.65 0.62
0.82 0.76
0.57 0.56
0.71 0.73
0.70 0.62
0.65 0.52
0.53 0.60
0.69 0.67
0.93 0.88
0.84 0.79
0.71 0.66
0.75 0.78
0.76 0.78
0.74 0.73
0.51 0.51
0.69 0.71
0.65 0.65
0.60 0.60
0.73 0.69
0.70 0.74
0.73 0.69
0.57 0.55
0.71 0.71
0.81 0.80
0.68 0.76
0.67 0.60
0.90 0.88
0.98 1.07
0.92 0.86
0.90 0.87
0.92 0.85
0.37 0.21
0.93 0.93
0.70 0.43
0.93 1.00
0.72 0.65
0.83 0.81
0.61 0.57
0.74 0.63
0.72 0.66
0.72 0.68
0.51 0.57
0.79 0.71
0.94 0.84
0.91 0.85
0.85 0.76
0.72 0.78
0.77 0.83
0.76 0.74
0.52 0.49
0.73 0.80
0.66 0.64
0.62 0.60
0.77 0.76
0.76 0.78
0.73 0.70
0.59 0.56
0.73 0.72
0.77 0.66
0.75 0.79
0.74 0.70
0.92 0.85
0.98 0.97
0.94 0.89
0.91 0.85
0.93 0.87
0.41 0.23
0.94 0.87
0.72 0.41
0.97 0.80
0.78 0.64
0.92 0.84
0.65 0.58
0.85 0.68
0.81 0.64
0.78 0.56
0.57 0.58
0.82 0.65
0.95 0.86
0.91 0.82
0.92 0.75
0.74 0.78
0.77 0.81
0.76 0.80
0.53 0.52
0.72 0.77
0.69 0.64
0.64 0.64
0.77 0.77
0.80 0.84
0.77 0.76
0.57 0.53
0.73 0.75
0.81 0.73
0.72 0.75
0.75 0.68
0.93 0.92
0.94 1.17
0.94 0.91
0.93 0.86
0.95 0.88
0.51 0.30
0.92 0.93
0.73 0.68
0.95 0.86
0.80 0.69
0.89 0.77
0.69 0.54
0.90 0.84
0.76 0.62
0.74 0.59
0.55 0.55
0.87 0.63
0.96 0.90
0.89 0.84
0.91 0.79
0.75 0.77
0.79 0.86
0.74 0.78
0.61 0.60
0.72 0.76
0.72 0.65
0.64 0.66
0.80 0.81
0.78 0.83
0.78 0.77
0.59 0.56
0.70 0.70
0.81 0.72
0.78 0.78
0.78 0.74
0.91 0.85
0.97 0.92
0.94 0.88
0.94 0.87
0.96 0.88
0.53 0.29
0.94 1.16
0.84 0.87
0.98 0.74
0.82 0.70
0.93 0.82
0.74 0.55
0.91 0.80
0.81 0.71
0.81 0.64
0.53 0.57
0.87 0.79
0.99 0.93
0.92 0.87
0.95 0.79
3 months 6 months 9 months 12 months 15 months 18 months
FIG. 3. The model accurately forecasts across variables. Relative errors of the model
(CRBM) and a random forest (RF) specifically trained to predict the value of a single variable at
a single time point. The root mean square (RMS) errors are scaled by the standard deviation of
the data to be predicted. Predictions are shown for every time-dependent variable except dropout.
At each time point and for each variable, the better of the random forest and CRBM predictions
is shown in bold.
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B. Simulating conditional patient trajectories
Predictions for any unobserved characteristics of a patient can be computed from our
model by generating samples from the model distribution conditioned on the values of all
observed variables. Sampling from the conditional distributions can be used to fill-in any
missing observations (i.e., imputation) or to forecast a patient’s future state. The ability to
sample from any conditional distribution is one advantage a modeling framework based on
CRBMs has over alternative generative models based on directed neural networks.
For each patient in the test set, we computed a forecast for their entire trajectory con-
ditioned on their baseline covariates. That is, we used the CRBM to numerically compute
the conditional expected value E[xi(t)|xi(t = 0)]. Next, we evaluated the root mean square
(RMS) error of the CRBM predictions on each variable at each time point past baseline.
For comparison, we trained a series of Random Forest (RF) models that use the baseline
data to predict each of the 35 time-dependent variables for all 6 time points. Note that
there is a separate RF model for each variable at each time point – a total of 210 different
RF models. We also trained an ensemble of 6 multivariate RFs – each one predicted all
35 covariates for a given time point – but were unable to get reasonable accuracies (see
Supporting Information). The RMS error of the random forest prediction sets a benchmark
for a predictive model that is specially trained for an individual problem. By contrast, a
single CRBM model is used to predict all variables, and all time points. Figure 3 presents
a detailed comparison between the single CRBM and the ensemble of 210 RF models. The
accuracy of the CRBM is close to the specialized RF model for each variable and time point,
with the CRBM generally outperforming the RF on the components of ADAS-Cog.
One can think of the ensemble of RF models as approximating the predictions of a
factorized generative model. That is, one could construct a simpler probabilistic model by
assuming that the variables are independent when conditioned on the baseline values, i.e.
p(x(t)|x(t = 0)) ≈ ∏j p(xj(t)|x(t = 0)). While this factorized model can make accurate
predictions for individual variables in isolation, it cannot generate realistic trajectories that
capture the correlations between the covariates (which will be zero by construction). By
contrast, the CRBM achieves equivalent accuracy on individual prediction problems while
also correctly modeling the correlation structure. More details on the comparison between
RFs and the CRBM are provided in the Supporting Information.
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In summary, stochastic simulations of disease progression have two main advantages
compared to supervised machine learning models that aim to predict a single, predefined
endpoint. The first is the simultaneous modeling of entire patient profiles in a way that cor-
rectly captures correlations between covariates. This allows for the quantitative exploration
of alternative endpoints and different patient subgroups. The second is that stochastic sim-
ulations provide in-depth estimates of risk for individual patients that can be aggregated
to estimate risks in larger patient populations. Moreover, our model provides accurate es-
timates of its uncertainty in addition to forecasts for expected progression of individual
patients (Figures S1 and S8). Patient heterogeneity manifests in more complex ways than
just a shift in the mean outcome – there are changes in the variance, skew, and shape of the
distribution of model predictions for each patient. Personalized approaches to AD therapy
will have to predict and address these different types of risk. The ability to simultaneously
compute predictions and confidence intervals for multiple characteristics of a patient is a
key feature of our approach and an important step towards comprehensive simulations of
disease progression.
C. Forecasting and interpreting disease progression
We now turn to disease progression to evaluate the CRBM and understand how it provides
interpretative power for MCI and AD. Our model is trained to simulate the evolution of the
individual components of the cognitive exams, laboratory tests, and clinical data. As a
result, it is also possible to simulate the evolution of any combination of these variables,
such as the 11-component ADAS-Cog score that is commonly used as a measure of overall
disease activity. Note that the ADAS delayed word recall component, which is present in the
dataset, is not part of the 11-component ADAS-Cog score but can be used as an additional
probe of disease severity, especially for MCI [44]. Figure 4A shows a box plot describing the
evolution of the ADAS-Cog score distribution within the population. The data and model
show the same trend – an increase in the mean ADAS-Cog score with time along with a
widening right tail of the distribution. This implies that much of the trend of increasing
ADAS-Cog scores in the population is driven by a subset of patients.
Simulations from the model can be run for each individual patient in order to forecast
their disease progression. Despite only being trained on data with a 3-month time lag, the
13
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FIG. 4. The model accurately forecasts progression and allows for interpretation. A)
Box plot of the ADAS-Cog score over time computed from the data and the model. The line
shows the mean, and the whiskers show the 10th and 90th percentiles. B) Out-of-sample predictive
accuracy for the change in ADAS-Cog score from baseline (i.e., t = 0) for different study durations.
Separate neural network, random forest, and linear regression models were trained to predict the
change in ADAS-Cog score from baseline for each study duration. The blue band shows the
uncertainty on the CRBM prediction. C) We created a simulated patient population with MCI
and an initial ADAS-Cog score of 10, and simulated the evolution of each synthetic patient for 18
months. The 5% of synthetic patients with the largest ADAS-Cog score increase were designated
“fast progressors” and the bottom 5% of patients with the smallest ADAS-Cog score increase were
designated “slow progressors”. Differences between the fast and slow progressors (the “absolute
effect size”) were quantified using the absolute value of Cohen’s d-statistic, which measures the
mean difference divided by a pooled standard deviation [45].
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model makes accurate predictions out to at least 18 months (Figure 4B). In Figure 4B, we
have compared the accuracy of the CRBM predictions for the change in ADAS-Cog score
from baseline to each possible endpoint in 3-month steps through 18 months to a variety
of supervised models (a linear regression, a random forest, and a deep neural network).
Each of the supervised models was trained to predict a specific endpoint (e.g., the change
in ADAS-Cog score after 6 months). The CRBM is the best performing model, though the
accuracies of the four types of predictors converge for time periods of 15 months or longer.
The strong relative performance of the CRBM on this task is remarkable given that (i) it
was only trained to perform 3-month ahead simulations and (ii) it was not directly trained
to predict the aggregate ADAS-Cog score. More details on the comparison are provided in
the Supporting Information.
To gain more insight into the origin of fast and slow progressing patients, we simulated
18-month patient trajectories conditioned on a baseline ADAS-Cog score of 10 and an initial
diagnosis of MCI. This initial ADAS-Cog score was chosen because it is representative of a
typical patient with MCI. The 5% of synthetic patients with the largest ADAS-Cog score
increase were designated “fast progressors” and the bottom 5% of synthetic patients with the
smallest ADAS-Cog score increase were designated “slow progressors”. Differences between
the fast and slow progressors (the “absolute effect size”) were quantified using the absolute
value of Cohen’s d-statistic [45], as shown in Figure 4C. The majority of baseline variables
are not associated with disease progression; however, there are strong associations with
cognitive tests based on recall (i.e., MMSE recall, ADAS word recall, and ADAS delayed
word recall) and word recognition. That is, patients with poor performance on the ADAS
delayed word recall test tend to progress more rapidly – even after controlling for the total
ADAS-Cog score. Variables associated with progression in patients who already have AD
are described in the Supporting Information.
IV. DISCUSSION
The ability to simulate the stochastic disease progression of individual patients in high
resolution could have a transformative impact on patient care by enabling personalized data-
driven medicine. Each patient with a given diagnosis has unique risks and a unique response
to therapy. Due to this heterogeneity, predictive models cannot currently make individual-
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level forecasts with a high degree of confidence. Therefore, it is critical that data-driven
approaches to personalized medicine and clinical decision support provide estimates of their
uncertainty in addition to expected outcomes.
Previous efforts for modeling disease progression in AD have focused on predicting
changes in predefined outcomes such as the ADAS-Cog score or the probability of conver-
sion from MCI to AD [16–29]. Here, we have demonstrated that an approach based on
unsupervised deep learning can create stochastic simulations of entire patient trajectories
that achieve the same level of performance on individual prediction tasks as specific models
while also accurately capturing correlations between variables. Deep learning-based gen-
erative models provide much more information than specific models, thereby enabling a
simultaneous and detailed assessment of different risks.
Our approach to modeling patient trajectories in AD overcomes many of the limitations
of previous applications of deep learning to clinical data [3, 8, 9, 11]. CRBMs can directly
integrate multimodal data with both continuous and discrete variables, and time-dependent
and static variables, within a single model. In addition, bidirectional models like CRBMs
can easily handle missing observations in the training set by performing automated impu-
tation during training. Combined, these factors dramatically reduce the amount of data
preprocessing steps needed to train a generative model to produce synthetic clinical data.
We found that a single time-lagged connection was sufficient for explaining temporal cor-
relations in AD; additional connections may be required for diseases with more complex
temporal evolution.
The utility of cognitive scores as a measure of disease activity for patients with AD has
been called into question numerous times [46]. Here, we found that the components of
the ADAS-Cog and MMSE scores were only weakly correlated with other clinical variables.
One possible explanation is that the observed stochasticity may simply reflect heterogeneity
in performance on the cognitive exam that cannot be predicted from any baseline mea-
surements. However, we did find that some of the individual components of the baseline
cognitive scores are predictive of progression. Specifically, patients with poor performance
on word recall tests tend to progress more rapidly than other patients, even after controlling
for the ADAS-Cog score.
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V. CONCLUSIONS
This work provides a proof-of-concept that patient-level simulations are technologically
feasible with the right tools and data. Nevertheless, there are a number of improvements to
our dataset and methodology that are important steps for future research. Here, we limited
ourselves to modeling 44 variables that are commonly measured in AD clinical trials. We
excluded some interesting covariates such as Leukocyte populations because they were not
measured in the majority of patients in our dataset constructed from the CAMD database.
We also lack data from neuroimaging studies and tests for levels of amyloid-β. Incorporating
additional data into our model development will be a crucial next step, especially as surrogate
biomarkers become a standard part of clinical trials.
The approach to simulating disease progression that we describe here can be easily ex-
tended to other diseases. Widespread application of deep generative models to clinical data
could produce synthetic datasets with lower privacy concerns than real medical data [10], or
could be used to run simulated clinical trials to optimize study design or as synthetic control
arms. In certain disease areas, tools that use simulations to forecast risks for specific indi-
viduals could help doctors choose the right treatments for their patients. Currently, progress
towards these goals is slowed by the limited availability of high quality longitudinal health
datasets and the limited ability of current machine learning methods to produce insights
from these datasets.
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VII. SUPPORTING INFORMATION
A. Data Processing
The CAMD database stores data using CDISC standards, specifically the Study Data
Tabulation Model (SDTM), which defines a common schema for clinical trial data and is
the required standard for clinical data submissions to the United States Food and Drug
Administration (FDA). In this format the data is already highly structured; therefore it is
possible to develop data processing pipelines that can apply to SDTM data in general and
not simply the particular database used here. We describe the general architecture of our
data processing pipeline and the CAMD-specific processing used.
The goal of our processing pipeline is to arrive at data that may be directly used by
machine learning algorithms to build patient-level models. This means:
• Data must be numerically formatted, such as numeric values, ordinal values for scores,
and one-hot encoding for categorical variables. For text or image data, this may involve
feature extraction, e.g. through a word2vec model or an autoencoder.
• Data must be patient-specific, and can extend over time in regular intervals. For
example, if we have cholesterol measurements for a given patient at 1, 2, 5, and 12
months, but are modeling the population at 3-month intervals, then we may average
the 1- and 2-month time point values and will have a missing entry between the 5-
and 12-month values.
Data arrives in Comma Separated Value (CSV) formatted text files, with abbreviation
encodings for file and variable names. Many of these abbreviation are generic to SDTM and
some apply specifically to disease areas. A translation table, such as one provided by CAMD,
may be used to automatically convert abbreviations to human-readable names. Using this
translation and simple type inference on variables, the data is ingested into a SQL database
via a simple script. We label this data in this form as the raw database.
The main component of the processing pipeline extracts data appropriate for training
and evaluating machine learning algorithms. This is done on a per-variable basis, meaning
the primary functions in the pipeline produce data for only a single variable; this processing
is then repeated over all variables of interest. Processed data is stored in the processed
21
database and may directly be used to construct datasets for machine learning. The steps in
the processing are:
• Declare which columns and tables from the raw database will be used to produce the
data for a given variable.
• Declare a processing function to convert this data into the appropriate form.
• Declare a location in the processed database where the data will be stored.
• Query the raw database for the data, apply the processing function, and store the
result in the processed database.
The processing functions may be common, such as one-hot encoding categorical labels, or
they may be custom, such as standardizing units for a particular laboratory measurement.
Such custom functions form the bulk of database-specific code that must be written. All of
the above processing steps can easily be encoded in configuration files, meaning the process
of preparing data for machine learning is simple and repeatable.
Finally, datasets may be constructed from the processed database by merely specifying
which variables are to be used. This step is also performed via a configuration file. Additional
filtering of patients, e.g. by requiring they have data present for a certain number of time
points, is straightforward to apply.
We have developed a python library to process data as described above. This library
fully handles the interface with the SQL database, has common data conversion functions,
and provides utilities to provide summary statistics and type inference for variables in a
dataset. For any specific project, such as the CAMD database, most of the processing is set
up by writing YAML configuration files that are simple, human-readable, and easily verified.
The remainder involves writing custom processing functions in python for specific variables.
This setup makes it straightforward to apply our machine learning models to other clinical
data modeling problems.
1. Variables Used in Training
Variables relevant to modeling AD progression were extracted from the CAMD database
using the method described above, and 44 variables without substantial missing data were
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Category Name Units Notes
ADAS Commands counts 0− 5 ordinal range
ADAS Comprehension counts 0− 5 ordinal range
ADAS Construction counts 0− 5 ordinal range
ADAS Delayed Word Recall counts 0− 10 ordinal range
ADAS Ideational counts 0− 5 ordinal range
ADAS Instructions counts 0− 5 ordinal range
ADAS Naming counts 0− 5 ordinal range
ADAS Orientation counts 0− 8 ordinal range
ADAS Spoken Language counts 0− 5 ordinal range
ADAS Word Finding counts 0− 5 ordinal range
ADAS Word Recall counts 0− 10 ordinal range
ADAS Word Recognition counts 0− 12 ordinal range
MMSE Attention and Calculation counts 0− 5 ordinal range
MMSE Language counts 0− 9 ordinal range
MMSE Orientation counts 0− 10 ordinal range
MMSE Recall counts 0− 3 ordinal range
MMSE Registration counts 0− 3 ordinal range
TABLE III. Cognitive variables included in the model.
identified and used for the model. Tables III and IV lists all variables, their units, and
specific processing considerations for each. Each laboratory test variable is converted to the
units given, and all transformations applied to train the models are inverted for analysis.
Of the 6500 patients in the CAMD database, very few have data after approximately 18
months from baseline. A 3-month (90-day) interval was a suitable interval such that most
patients have data at every time point; shorter intervals yielded groups of patients without
data at some time points. Therefore, we chose to represent all temporal variables in 3-month
intervals from 0 (baseline) to 18 months, giving 7 available time points for each patient.
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2. Patients Used in Training
To model progression, we are most interested in patients with longer trajectories. There-
fore, we selected the 1908 patients that have data at the 15- or 18-month time points. These
patients were randomly divided into three groups: training (1335 patients, or 70%), valida-
tion (95 patients, or 5%), and testing (478 patients, or 25%). The CRBM is trained only
on the training group, with the validation group used to evaluate the model’s performance
during training. The supervised models predicting progression are trained on the combina-
tion of the training and validation groups using 5-fold nested cross validation. Analysis is
performed only on the testing group.
B. Motivation for CRBMs
Boltzmann machines are a well-known, standard machine learning algorithm for modeling
relationships between data. They provide several features critical to modeling clinical data
not found in most machine learning models:
• They can easily model multimodal data. Different neuron types may be used to model
continuous numeric, ordinal, Bernoulli, or categorical data.
• They allow for conditional and generative sampling. If some clinical data is known for
a patient, it can be used to predict unknown data for that patient. For example, an
initial population of an AD clinical trial may be defined in terms of standard inclusion
criteria, such as age, sex ratio, and ADAS-Cog scores, and the remaining baseline data
and any future data may be predicted.
• As a consequence, they naturally handle missing data. The model itself may be used
to impute missing values from the learned joint probability distribution of the data.
This may be done during training, meaning missing data can be directly fed into the
model.
• They are stochastic, meaning data may be sampled. Stochastic models naturally
provide an estimate of their uncertainty through this sampling. For clinical data, the
consequence is that the model returns both a prediction and an uncertainty for any
clinical variable being predicted.
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Conditional Restricted Boltzmann Machines [36–39] provide a way to model time series
data using the natural capabilities of Boltzmann machines. Our CRBM contains the visible
units for multiple time points, with a standard hidden layer. The visible units are organized
as:
vCRBM = vstatic ⊕ vt ⊕ · · · ⊕ vt+k , (2)
where k is the time lag of the model. In our model, we use k = 1, so that two time points
are learned simultaneously. The static units are only used once, as they are constant over
all times. The model learns the complete joint probability distribution between all k + 1
adjacent time points simultaneously. That means that any conditional sampling of the data
may be performed, such as predicting the data for a time point given the previous k time
points. A baseline cohort may be simulated by sampling from the model and using the first
time point. This treatment of the data to allow for learning inter-dependence between time
points is the only distinction of a CRBM over a standard RBM.
C. Details of Training
The CRBM is trained on the data from adjacent pairs of time points. If xt is the vector of
time-dependent variables for a patient at time t and xstatic is the vector of static variables for
the same patient, then the visible units used to train the CRBM are v = {xt+1,xt,xstatic}, a
concatenation of the data from the adjacent time points t and t+ 1 with the static variables
represented only once.
When training the CRBM, the data for each patient in the training and validation groups
are reorganized into all adjacent pairs of frames. Since each patient has data for 7 time
points, they contribute 6 pairs of time points (which we will call samples). Inside of each
group samples are all shuffled so that minibatches contain a mixture of patients and times.
The CRBM has a single hidden layer of 50 ReLU units, and is trained using the methods
described in [42]. The objective function C is a linear combination of log-likelihood L and
adversarial A objectives,
C = −γL − (1− γ)A , (3)
where γ is a parameter weighing the relative size of the two objectives. Parameters used to
train the CRBM are listed in Table V. The training setup is similar to those used in [42]; here
we use a random forest classifier for the adversary. Temperature-driven sampling, where the
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temperature is sampled from an autocorrelated Gamma distribution, is not used, though
the model performance is not especially sensitive to this choice.
Notable dynamics were observed during the training process. Within 100 epochs, metrics
monitored during training such as KL divergence and reverse KL divergence achieve values
close to their final values. Sampling from the model at this stage, the model has relatively
poorer performance for patients with extremal ADAS-Cog scores than those near the mode.
Most importantly, during the early stages of training the model has a strong regression to
the mean effect for ADAS-Cog score outliers, where the model predicts patients with a low
score progress rapidly and those with a high score improve – the opposite of what is observed
in the data. Continuing training allows the model to unlearn this behavior and correctly
learn a progression from the mean, where higher scoring individuals progress more rapidly.
We expect that this feature of training, where it takes a longer time to effectively learn the
behavior of outliers, is common.
1. Details of Progression Predictions
This subsection gives details on the modeling for Figure 4B. A linear regression, random
forest regression, and neural network were trained to predict the ADAS-Cog score change
from the baseline patient data at a single given readout time. The CRBM is also used to
predict the same score change. The performance of all the algorithms are very similar; it
is likely additional patients or additional data predictive of patient progression would be
needed to substantially improve the performance of the models. For example, we found
that the addition of the ApoE 4 allele count to the baseline variables decreases the RMS
error by 5–10%. This section gives details on the training of the supervised models and the
evaluation of all models.
The supervised models are trained from the baseline time point data to predict the ADAS-
Cog score change from baseline to readout. All possible time points (3, 6, 9, 12, 15, and
18 months) are used as readout times, and separate supervised models must be trained for
each readout time. The same CRBM model may be used for all readout times.
However, there is missing data for many patients. We exclude any patients that having
any missing ADAS-Cog components at baseline or readout, ensuring that valid labels can
be defined. We mean impute other missing baseline variables from the training data. After
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this screening, the number of training patients for the supervised algorithms and testing
patients for all algorithms as a function of readout time is given in Table VI.
The supervised algorithms are trained using 5-fold nested cross validation, drawing sam-
ples from the same dataset as the training and validation samples for the CRBM. For the
neural network, only one set of hyperparameters was chosen and so there was only a single
cross validation loop. All algorithms are evaluated on the same test set. Table VII gives
the architectures and hyperparameters for each of the supervised algorithms. Note that for
the supervised algorithms, a new model was trained for every timepoint, while the CRBM
is the same model over all timepoints.
Once trained, the supervised algorithms are used to predict the ADAS-Cog score change
for the test data, and a root mean square (RMS) error over the test set is computed. This
is done for each readout time. The predictions for the CRBM (over all readout times) are
obtained by repeatedly simulating patient trajectories from the baseline time point. For
each simulation, the ADAS-Cog score change is recorded, yielding a distribution of score
changes for each patient that represents the probabilistic distribution of predictions made
by the CRBM. The mean of this distribution is the prediction of the CRBM for the given
patient. The RMS error of these predictions is computed, as well as its standard error.
These results make up the data shown in Figure 4B.
2. Details of Trajectory Progression Predictions
This subsection gives details on the modeling for Figure 3. The approach is the natural
extension of the methodology described in the previous subsection.
A random forest is trained to predict a single time-dependent variable at a single readout
time, meaning over all 35 time-dependent variables and all 6 possible readout times, 210
different random forest models are trained. The input data are the baseline variables, with
mean imputation used in the case of missing data. Samples where either the baseline value
or the readout value (the label) are missing are excluded. The root mean square (RMS)
error is computed over the test data, again only using samples where the variable being
modeled is present at both baseline and the readout time. For the CRBM, predictions are
made by repeatedly simulating patients conditioned on their baseline data, and taking the
mean for each patient as the CRBM prediction. The RMS error can then be computed,
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using the same test samples on which the random forest models were evaluated.
It is helpful to normalize these errors by the standard deviation of the value to be pre-
dicted. An error ratio of 1 implies that the prediction is no better than predicting the mean
of the test data, and an error ratio well below 1 implies that the prediction is highly precise
at a per-patient level.
D. Additional Results
There are many ways to study the performance of an unsupervised model, so we take the
opportunity to present additional results that provide more insight into the CRBM.
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FIG. 5. Stochastic simulations enable individual assessments of risk. Violin plots display
the stochastic evolution of an MCI patient whose ADAS score change over 18 months suggests a
conversion to AD. The width of the blue bars represents the probability computed using simulations
from the CRBM, and the mean CRBM prediction is shown as the black line. The red dots show
the actual observed values from the chosen patient. The CRBM was initialized with the observed
values at baseline (t = 0). Then, we repeatedly simulated 18-month trajectories and created
histograms of each variable at every time point. The model predicts trends and imputes values
when observations are missing for the patient (e.g., lab scores such as cholesterol and hematocrit).
Units for these data are given in Table IV.
29
[15] J. Cummings, P. S. Aisen, B. DuBois, L. Fro¨lich, C. R. Jack, R. W. Jones, J. C. Morris,
J. Raskin, S. A. Dowsett, and P. Scheltens, Alzheimer’s research & therapy 8, 39 (2016).
[16] J. A. Rogers, D. Polhamus, W. R. Gillespie, K. Ito, K. Romero, R. Qiu, D. Stephenson, M. R.
Gastonguay, and B. Corrigan, Journal of pharmacokinetics and pharmacodynamics 39, 479
(2012).
[17] K. Ito, B. Corrigan, K. Romero, R. Anziano, J. Neville, D. Stephenson, and R. Lalonde,
Journal of Alzheimer’s Disease 37, 173 (2013).
[18] R. E. Kennedy, G. R. Cutter, G. Wang, and L. S. Schneider, Journal of Alzheimer’s Disease
50, 1205 (2016).
[19] I. Tishchenko, C. Riveros, P. Moscato, and C. A. M. Diseases, Future science OA 2, FSO140
(2016).
[20] B. Szalkai, V. K. Grolmusz, V. I. Grolmusz, et al., Archives of gerontology and geriatrics 73,
300 (2017).
[21] S. G. Mueller, M. W. Weiner, L. J. Thal, R. C. Petersen, C. R. Jack, W. Jagust, J. Q. Tro-
janowski, A. W. Toga, and L. Beckett, Alzheimer’s & dementia: the journal of the Alzheimer’s
Association 1, 55 (2005).
[22] S. L. Risacher, A. J. Saykin, J. D. Wes, L. Shen, H. A. Firpi, and B. C. McDonald, Current
Alzheimer Research 6, 347 (2009).
[23] C. Hinrichs, V. Singh, G. Xu, S. C. Johnson, A. D. N. Initiative, et al., Neuroimage 55, 574
(2011).
[24] K. Ito, B. Corrigan, Q. Zhao, J. French, R. Miller, H. Soares, E. Katz, T. Nicholas, B. Billing,
R. Anziano, et al., Alzheimer’s & dementia: the journal of the Alzheimer’s Association 7, 151
(2011).
[25] H.-I. Suk and D. Shen, in International Conference on Medical Image Computing and
Computer-Assisted Intervention (Springer, 2013) pp. 583–590.
[26] H.-I. Suk, S.-W. Lee, D. Shen, A. D. N. Initiative, et al., NeuroImage 101, 569 (2014).
[27] S. Liu, S. Liu, W. Cai, S. Pujol, R. Kikinis, and D. Feng, in Biomedical Imaging (ISBI), 2014
IEEE 11th International Symposium on (IEEE, 2014) pp. 1015–1018.
[28] A. Ortiz, J. Munilla, J. M. Gorriz, and J. Ramirez, International journal of neural systems
26, 1650025 (2016).
30
[29] J. Samper-Gonzalez, N. Burgos, S. Fontanella, H. Bertin, M.-O. Habert, S. Durrleman, T. Ev-
geniou, O. Colliot, A. D. N. Initiative, et al., in International Workshop on Machine Learning
in Medical Imaging (Springer, 2017) pp. 53–60.
[30] B. Corrigan, K. Ito, J. Rogers, D. Polhamus, D. Stephenson, and K. Romero, in Applied
Pharmacometrics (Springer, 2014) pp. 451–476.
[31] K. Romero, K. Ito, J. Rogers, D. Polhamus, R. Qiu, D. Stephenson, R. Mohs, R. Lalonde,
V. Sinha, Y. Wang, et al., Clinical Pharmacology & Therapeutics 97, 210 (2015).
[32] K. Romero, M. De Mars, D. Frank, M. Anthony, J. Neville, L. Kirby, K. Smith, and
R. Woosley, CliniCAl pHArmACology & THerApeuTiCs 86, 365 (2009).
[33] J. Neville, S. Kopko, S. Broadbent, E. Avile´s, R. Stafford, C. M. Solinsky, L. J. Bain, M. Cis-
neroz, K. Romero, and D. Stephenson, Alzheimer’s & dementia: the journal of the Alzheimer’s
Association 11, 1212 (2015).
[34] W. R. Kubick, S. Ruberg, and E. Helton, Drug information journal 41, 373 (2007).
[35] S. Hume, J. Aerts, S. Sarnikar, and V. Huser, Journal of biomedical informatics 60, 352
(2016).
[36] D. H. Ackley, G. E. Hinton, and T. J. Sejnowski, Cognitive science 9, 147 (1985).
[37] G. Hinton, Momentum 9, 926 (2010).
[38] G. W. Taylor, G. E. Hinton, and S. T. Roweis, in Advances in neural information processing
systems (2007) pp. 1345–1352.
[39] V. Mnih, H. Larochelle, and G. E. Hinton, in Proceedings of the Twenty-Seventh Conference
on Uncertainty in Artificial Intelligence (AUAI Press, 2011) pp. 514–522.
[40] J. Tubiana and R. Monasson, Physical review letters 118, 138301 (2017).
[41] T. Tieleman, in Proceedings of the 25th international conference on Machine learning (ACM,
2008) pp. 1064–1071.
[42] C. K. Fisher, A. M. Smith, and J. R. Walsh, arXiv preprint arXiv:1804.08682 (2018).
[43] F. K. Dankar and K. El Emam, Transactions on Data Privacy 6, 35 (2013).
[44] M. Sano, R. Raman, J. Emond, R. G. Thomas, R. Petersen, L. S. Schneider, and P. S. Aisen,
Alzheimer Dis Assoc Disord 25, 122 (2011).
[45] J. Cohen, Statistical power analysis for the behavioral sciences (Lawrence Erlbaum Associates,
1988).
31
[46] J. F. Benge, S. Balsis, L. Geraci, P. J. Massman, and R. S. Doody, Dementia and geriatric
cognitive disorders 28, 63 (2009).
32
Category Name Units Notes
Laboratory Alanine aminotransferase µkat/l log-standarized for training
Laboratory Alkaline phosphatase µkat/l log-standarized for training
Laboratory Aspartate aminotransferase µkat/l log-standarized for training
Laboratory Cholesterol mmol/l log-standarized for training
Laboratory Creatine kinase iu/cl log-standarized for training
Laboratory Creatinine mg/dl log-standarized for training
Laboratory Gamma glutamyl transferase iu/dl log-standarized for training
Laboratory Hematocrit counts log-standarized for training
Laboratory Hemoglobin g/dl log-standarized for training
Laboratory Hemoglobin a1c % log-standarized for training
Laboratory Indirect bilirubin mg/dl log-standarized for training
Laboratory Potassium mmol/l log-standarized for training
Laboratory Sodium mmol/cl log-standarized for training
Laboratory Triglycerides g/l log-standarized for training
Clinical Blood pressure (diastolic) mmHg log-standarized for training
Clinical Blood pressure (systolic) mmHg log-standarized for training
Clinical Heart rate bpm log-standarized for training
Clinical Weight kg log-standarized for training
Clinical Dropout - 1 for dropout before the next time
Background Age at baseline Years ‘>89’ → 90, log-stdized for training
Background Geographic region - 1-hot, 7 labels built from country
Background Initial diagnosis (AD or MCI) - Bernoulli
Background Past cardiovascular event - Bernoulli
Background ApoE 4 allele count counts 0, 1, or 2
Background Race - 1-hot, 6 labels
Background Sex - Bernoulli, 1 if female
Background Height cm log-standarized for training
TABLE IV. Laboratory, clinical, and background variables included in the model.
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Hyperparameter Value / Notes
number of epochs 2000
batch size 100
training/validation fractions 95% / 5%
learning rate 0.005 initial; 0 final; linear decay
optimizer ADAM, beta (0.9, 0.999)
Monte Carlo steps (sampling) 50
Monte Carlo steps (imputation) 2
driven sampling β 0
likelihood weight γ (Equation 3) 0.3
adversary random forest, 5 trees with max depth 5
TABLE V. Hyperparameters used to train the CRBM.
Readout Time [months] Training Patients Testing Patients
3 1404 468
6 1401 467
9 1392 461
12 1392 461
15 1402 468
18 1285 439
TABLE VI. Number of training and testing patients used to predict ADAS-Cog score progression
as a function of readout time.
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Model Architecture Hyperparameters
Linear Regression ridge (L2 regularization) α ∈ {10k}2k=−3
Random Forest 100 trees max depth ∈ {2k}6k=2
Neural Network
2 hidden layers (30, 10) units
ReLU activations
ADAM learning rate = 0.02
batch size = 25
20 epochs
TABLE VII. Supervised models used to predict ADAS-Cog score progression.
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FIG. 6. Marginal distributions in the generative mode for all variables. The CRBM is
used to generate 18-month patient trajectories, with the same number of virtual patients as the
number of patients in the test group. The marginal distributions for the patients and the CRBM
are shown for all variables. Note that some variables are constant over the virtual and real patients
given the relatively small sample size (478 patients).
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FIG. 7. Marginal distributions conditioned on baseline for cognitive variables. The
CRBM is conditioned on the patient data at baseline, and one trajectory is simulated for each
patient. The marginal distributions for the patients and the CRBM are shown for temporal vari-
ables. Because the CRBM is conditioned on the data at baseline, the 0-month distributions always
match except when the data is missing values and the model performs imputation.
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FIG. 8. Marginal distributions conditioned on baseline for clinical variables. The CRBM
is conditioned on the patient data at baseline, and one trajectory is simulated for each patient. The
marginal distributions for the patients and the CRBM are shown for temporal variables. Because
the CRBM is conditioned on the data at baseline, the 0-month distributions always match except
when the data is missing values and the model performs imputation.
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FIG. 9. Goodness-of-fit. A) Correlations between variables as predicted by the model (below
the diagonal) conditioned on the data at baseline (t = 0) and calculated from the data (above the
diagonal). Components of the cognitive scores are strongly correlated with each other, but not
with other clinical data. B) Scatterplot of observed vs predicted correlations for each time point,
over all times. C) Scatterplot of observed vs predicted autocorrelations with time lag of 3 months.
D) Scatterplot of observed vs predicted autocorrelations with time lag of 6 months. Color gradient
in B-D represents the fraction of observations where the variables used to compute the correlation
were present; lighter colors mean more of the data was missing. This figure is a complement to
Figure 2.
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Patients with an AD diagnosis and a baseline ADAS-Cog of 20
FIG. 10. Using simulations to interpret prognostic signals for AD progression. We
created a simulated patient population with AD and an initial ADAS score of 20 (typical for AD),
and simulated the evolution of each virtual patient for 18 months. The 5% of virtual patients with
the largest ADAS score increase were designated “fast progressors” and the bottom 5% of patients
with the smallest ADAS score increase were designated “slow progressors”. Differences between
the fast and slow progressors (the “absolute effect size”) were quantified using the absolute value
of Cohen’s d-statistic. This figure is a complement to Figure 4C.
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FIG. 11. Confidence in ADAS score progression by the CRBM. For each patient with
a valid ADAS score at baseline and 18 months, the CRBM is used to repeatedly simulate 18-
month trajectories. The mean of the ADAS score changes from these trajectories is the CRBM
prediction, and the standard deviation is a measure of the CRBM confidence. These values are
used to compute a standard z score for each patient by taking the difference between the CRBM
prediction and the true ADAS score change and dividing by the standard deviation of predictions.
These z scores are 0-centered, tend to be fairly normally distributed (A), and do not correlate with
the CRBM confidence (B).
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FIG. 12. Predictions of ADAS score progression for example patients. Starting with
baseline data for 3 example patients, the CRBM was used to predict the change in ADAS score
over 18 months. By repeatedly simulating trajectories for each patient, the CRBM provides a set
of predictions per patient that forms a probability distribution. The mean of this distribution is
the CRBM prediction, which is compared with the true value of the ADAS score change for the
patient. The width of the distribution is a measure of the confidence of the CRBM prediction.
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FIG. 13. Expected evolution of ADAS score components for example patients. Starting
with baseline data for 3 example patients, the CRBM was used to repeatedly simulate 18-month
trajectories for each patient. The mean value of each of the ADAS-Cog score components for each
time point is shown as a blue bar, demonstrating the ability of the CRBM to simulate the granular
ADAS score components. The total mean ADAS score for each time point is shown at the top.
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FIG. 14. The model accurately forecasts across variables. Relative errors of the model
(CRBM) and a “global” random forest (RF(g)) trained to predict the value of all variables at a
single time point. The root mean square (RMS) errors are scaled by the standard deviation of the
data to be predicted. Predictions are shown for every time-dependent variable except dropout.
At each time point and for each variable, the better of the random forest and CRBM predictions
is shown in bold. The CRBM strongly outperforms the global random forest. This figure is a
complement to Figure 3, where here the random forest is trained to predict all variables at a time
point instead of having separate random forests for each variable.
43
